Please assess the completion status of the following clinical trial:

Trial Title: Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Male~* 18-65 years old~* BMI between 18-40~* Not participated in clinical trial and received either an investigational or marketed drug within two months prior to the study~* Not donated blood in previous two months~Exclusion Criteria:~* Women~* History of local or systemic infection disease with fever or requiring antibiotic within 4 weeks of drug administration~* Corrected QT interval above normal~* Laboratory test results that is more than 1.5 fold outside normal range and/or is judged to be clinically significant~* Current addition to alcohol or substances of abuse~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation~* Use of system course of corticosteroids or other medication known to cause insulin resistance in previous 6 weeks~* Hyperthyroidism,hypothyroidism, hypertension (even if controlled with medications), heart disease (including CAD and CHF), cardiac arrhythmias, diabetes, unstable vasomotor system, or use of monoamine oxidase (MAO) inhibitors~* Diagnosis of bladder outlet obstruction or use of any medication to treat overactive bladder (e.g. Tolterodine, Solifenacin, Propiverine, Oxybutynin, and Fesoterodine)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- beta3-adrenergic receptor agonist (Type: EXPERIMENTAL): single dose. Each subject was randomized to receive placebo at one visit and then the beta3-adrenergic receptor agonist on another study day.

Based on this trial design, predict the completion outcome and termination type (if applicable).